## **EISAI ESTABLISHES HOLDING COMPANY** EISAI CHINA HOLDINGS LTD. IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has established a holding company Eisai China Holdings Ltd. in Suzhou, Jiangsu Province, China. Eisai China Holdings Ltd. is a subsidiary of Eisai Asia Regional Services Pte. Ltd. which is Eisai's representative subsidiary for Asia located in Singapore.

With the establishment of this new company, Eisai China Holdings Ltd. will integrate the Chinese domestic subsidiaries Eisai China Inc. and Eisai (Suzhou) Trading Co. Ltd., strengthen various functions including accounting, legal and compliance, and also create a flexible capital transfer system to respond to capital demands, in order to optimize the management of imn9of4(i)3h.j 0 Tc4MTd [resl p(n9of4(i)3), 98l3oi0 Tw 0.843Dofio3 expected to achieve strong double digit growth into the future.

<sup>1</sup> Through the establishment of Eisai China

Holdings Ltd., Eisai plans to further enhance its pharmaceutical production, sales and supply systems in China, and through the of the Board; Wenqin Yue, President

Planning and execution of strategy, consolidated finance and

accounting, internal auditing

Capital: 30 million U

**Business:** 

hehe.

## [Notes to editors]

## 1. About the Chinese pharmaceutical market

Due to various factors including population growth, the aging of the population and the implementation of a public healthcare system, the Chinese pharmaceutical market is exhibiting strong growth. In 2013, the size of the market was valued at 86.8 billion U.S dollars (approximately 9.1 trillion yen), and grew 16% compared to the previous year.<sup>2</sup> While policies to reduce drug prices have been promoted in order to reduce healthcare expenditure, healthcare needs are rising due to the expansion of the middle class, and the Chinese pharmaceutical market is expected to achieve strong double digit growth into the future (expected compound annual growth rate 12.9% over the 5-year period from 2014).<sup>1</sup>

## 2. About Eisai's subsidiaries in China

1) Eisai China Inc.

Location: Suzhou, Jiangsu Province, China

Representatives: Yoshiyuki Ose, Chairman of the Board; Yanhui Feng, President

Scope of Business: Manufacture and sales of pharmaceutical products

Charter Capital: 78.54 million U.S. dollars

Date of Establishment: March 1996

2) Eisai (Suzhou) Trading Co., Ltd.

Location: Suzhou, Jiangsu Province, China

Representative: Yanhui Feng, Executive Director and President

Scope of Business: Wholesale, import and export of active pharmaceutical ingredients,

pharmaceutical formulations and biopharmaceuticals, intermediate trade, etc.

Charter Capital: 700 million Chinese yuan

Date of Establishment: October 2010

- 1 ©2014 IMS Health, Forecasting to 2018: Outlook for the Pharmaceutical Markets in the UK, China and Japan, reproduction prohibited
- 2 ©2014 IMS Health, IMS World Review Analyst, reproduction prohibited